News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2011

Epigenomics AG: Partner Quest Diagnostics Septin9 Test ColoVantage Approved by New York State

Berlin, Germany, and Seattle, WA, USA 18.03.2011 | 110318_Press_release_Quest_Diagnostics Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today informed that the colorectal cancer blood test ColoVantage™ developed and offered in the U.S. by its partner Quest Diagnostics Incorporated (NYSE:DGX) has been approved by the New York State’s Department of Health.

Read more

Epigenomics and QIAGEN Sign Collaboration Agreement in Colorectal Cancer Blood Testing

QIAGEN acquires options to mSEPT9 biomarker and DNA methylation technologies; QIAGEN granted license to pursue Septin9 product related R&D

Read more

Epigenomics AG signs Collaboration Agreement in Colorectal Cancer Blood Testing with QIAGEN N.V.

PDF 12.4 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A0BVT96) today signed an option agreement in colorectal cancer blood testing with QIAGEN N.V. (ISIN: NL0000240000). Under the terms of the agreement, QIAGEN receives an option to a worldwide non-exclusive commercial license to Epigenomics’ proprietary mSEPT9 biomarker and DNA methylation technologies for the detection of colorectal cancer in […]

Read more

Epigenomics Provides Update on Progress with US Product Development for Epi proColon

 Strong feasibility study data for improved product concept with 91% sensitivity and 87% specificity – FDA sets February date for Pre-IDE meeting

Read more

Epigenomics Appoints Thomas Taapken as New CFO, Effective April 1, 2011

Brings significant U.S. experience and strategic transactions expertise

Read more